• Infobionics

  Participated · Series B · Apr 2014

  InfoBionics develops the cloud-based MoMe System and a Class 2 medical device aimed at detecting cardiac arrhythmias. The company says MoMe enables a seamless transition between holter, event, and mobile cardiac telemetry monitoring modes. The platform is also intended to track other chronic conditions. InfoBionics is led by Nancy Briefs and is preparing to roll out the first application of its Class 2 device later this year. The company completed the first tranche of a $17 million Series B as it raises fresh capital to support commercialization. The cardiac monitoring industry is cited in the article as an approximately $3 billion market, and digital medical devices attracted $146 million in venture investment last year.

• InfoBionic

  Participated · Series B · Apr 2014

  InfoBionic develops the MoMe® ARC platform, a third-generation virtual telemetry system for remote, wireless monitoring and diagnosis of cardiac arrhythmias. Its MoMe® ARC 4-in-1 monitor pairs a 3rd-generation remote ECG device with a Bluetooth diagnostic 6-lead sensor and offers both patch-type and wire-based sensors. The system delivers heartbeat-to-heartbeat, full-disclosure ECG data over the cloud to provide near real-time, hospital telemetry-level access for clinicians. The company recently received FDA approval for the third-generation MoMe® ARC platform. InfoBionic plans to use the Series D proceeds to continue commercial expansion of the MoMe® ARC system. The company is led by CEO Stuart Long. InfoBionic develops the MoMe® Kardia remote cardiac monitoring platform that provides physicians 24/7 on-demand access to full-disclosure Holter, Event, and MCT data via a HIPAA-compliant portal. The system is positioned to replicate in-hospital telemetry data in the outpatient setting and was granted FDA 510(k) clearance in 2015. The company targets an addressable U.S. market estimated at $1.4 billion and recently announced a commercial distribution partnership to enhance market penetration. InfoBionic reports month-to-month subscription growth rates exceeding 35% since this time last year. The completed financing is intended to support continued commercial expansion of the MoMe® Kardia system. InfoBionic develops the MoMe® Kardia system, a cloud-based remote patient monitoring platform for cardiac arrhythmia detection. The platform streams continuous electrocardiogram, respiration and motion data to the cloud for analysis and delivers automated reporting to mobile devices, tablets and web portals. It provides on-demand, actionable monitoring data and analytics for Holter, Event and mobile cardiac telemetry (MCT) directly to physicians. The company is led by Nancy Briefs, President, CEO and Co-Founder. InfoBionic raised a financing round to support commercialization of the MoMe® Kardia system. The articles report the company is based in Lowell, Massachusetts. InfoBionic is an emerging digital health company focused on providing anywhere, anytime access to cardiac event monitoring with improved event detection and clinical efficacy through a lower-cost business model. Its lead product, the MoMe System, is a cloud-based, multi-pass analysis universal remote patient monitoring platform that provides seamless transition between Holter, Event, and Mobile Cardiac Telemetry monitoring modes in one device. MoMe Kardia is positioned to address the roughly $3B worldwide cardiac monitoring market by delivering enhanced analytics and on-demand access to patient data for diagnosis. Proceeds from the recently closed Series B tranche will enable commercialization of the MoMe System in Europe and the United States. The company emphasizes cloud technology to improve patient monitoring, diagnosis and treatment while reducing operating and healthcare costs. Safeguard Scientifics’ participation and board representation signal strategic support for commercialization and growth.

• Raven360

  Participated · Series A · Jun 2013

  Raven360 offers Digital Academies that let marketing teams embed knowledge-rich learning environments into their websites so prospects can research, demo and purchase products on their own terms. By aligning seller content with buyer problems from the first interaction, the platform turns web visitors into informed product evaluators and ultimately qualified leads. These academies generate predictive insights into each prospect’s stage in the buying journey, enabling marketing and sales teams to support buyer-led purchases more effectively. Fast-growing companies worldwide use Raven360 to onboard, teach, coach and inspire customers, partners and employees. With its newly raised capital, the company will expand sales and marketing, enhance the user experience and interface, and integrate machine-learning and AI capabilities to deepen engagement. Headquartered in Marlborough, Massachusetts, Raven360 positions itself as a critical tool in the modern CMO’s toolkit for creating top-of-funnel opportunities.

• Avaxia Biologics

  Participated · Series B · Jun 2013

  Avaxia’s lead clinical candidate is AVX-470, an orally administered, gut-targeted anti-TNF antibody being developed as a potential first-line therapy for inflammatory bowel disease (IBD). The company initiated a Phase 1b clinical trial of AVX-470 in patients with active ulcerative colitis. Avaxia uses a proprietary oral antibody platform to develop minimally absorbed drugs that act locally in the gastrointestinal tract and is pursuing additional indications including type 2 diabetes, celiac disease, GI acute radiation syndrome, and oral mucositis. Avaxia controls all rights to its products and programs and is actively seeking collaborations. The company recently closed a Series B financing to fund clinical development activities and advance its lead program. Avaxia Biologics is a Lexington, MA–based biotech developing orally delivered antibody drugs that act locally within the gastrointestinal tract. Its lead development efforts include an orally active anti-TNF for inflammatory bowel disease and AVX-470 for GI acute radiation syndrome. The company also targets celiac disease, oral mucositis, diabetes and obesity with its oral antibody platform. Avaxia intends to use new capital to manufacture its orally active anti-TNF for an upcoming clinical trial and to complete final preclinical studies ahead of a Phase 1B trial in IBD patients. In addition to private financing, Avaxia has received funding from BARDA to support AVX-470 development. The company is led by founder and CEO Dr. Barbara Fox, and recently added Henry Kay (Boston Harbor Angels, Launchpad Venture Group) to its board.

No current team members are available.